Instrument Inactif

Communiqués Yumanity Therapeutics

Actions

YMTX

US98872L1026

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K	11/05/23	PU
Yumanity Therapeutics : Regulation FD Presentation - Form 8-K	17/04/23	PU
Yumanity Therapeutics : VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 - Form 8-K	12/04/23	PU
Yumanity Therapeutics : January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) - Form 8-K	05/01/23	PU
Yumanity Therapeutics : Kineta Completes Reverse Merger with Yumanity Therapeutics - Form 8-K	22/12/22	PU
YUMANITY THERAPEUTICS, INC. Other Events (form 8-K/A)	16/12/22	AQ
Yumanity Therapeutics : Acquisition/Asset Disposal - Form 8-K	15/12/22	PU
YUMANITY THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits (form 8-K)	15/12/22	AQ
YUMANITY THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	13/12/22	AQ
YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	06/12/22	AQ
YUMANITY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	05/12/22	AQ
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta	05/12/22	GL
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta	05/12/22	GL
YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	01/12/22	AQ
Yumanity Therapeutics : Kineta to Participate in JMP Securities Hematology and Oncology Summit - Form 8-K	30/11/22	PU
YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	29/11/22	AQ
YUMANITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	15/11/22	AQ
YUMANITY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	14/11/22	AQ
YUMANITY THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	14/11/22	AQ
Yumanity: Q3 Earnings Snapshot	14/11/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Yumanity Therapeutics

Actions

YMTX

US98872L1026

Communiqués

Filtres